LGALS3 and ischemic cardiomyopathy: Importantly, Kaplan–Meier analysis demonstrated that Gal-3 ≥ 13.13 ng/mL was able to predict AIT in patients with both ischemic cardiomyopathy (ICM) and non-ischemic cardiomyopathy (NICM) [103].